Management of multidrug-resistant TB: novel treatments and their expansion to low resource settings

Lewis, Joseph M and Sloan, Derek (2016) 'Management of multidrug-resistant TB: novel treatments and their expansion to low resource settings'. Transactions of the Royal Society of Tropical Medicine and Hygiene, Vol 10, Issue 3, pp. 163-172.

Full text not available from this repository.

Abstract

Despite overall progress in global TB control, the rising burden of multidrug-resistant TB (MDR-TB) threatens to undermine efforts to end the worldwide epidemic. Of the 27 countries classified as high burden for MDR-TB, 17 are in ‘low’ or ‘low–middle’ income countries. Shorter, all oral and less toxic multidrug combinations are required to improve treatment outcomes in these settings. Suitability for safe co-administration with HIV drugs is also desirable. A range of strategies and several new drugs (including bedaquiline, delamanid and linezolid) are currently undergoing advanced clinical evaluations to define their roles in achieving these aims. However, several clinical questions and logistical challenges need to be overcome before these new MDR-TB treatments fulfil their potential.

Item Type:	Article
Additional Information:	Access: SM http://creativecommons.org/licenses/by/4.0/ Subjects: SM
Subjects:	WA Public Health > WA 30 Socioeconomic factors in public health (General) WC Communicable Diseases > WC 20 Research (General) WF Respiratory System > Tuberculosis > WF 200 Tuberculosis (General) WF Respiratory System > Tuberculosis > WF 360 Drug therapy
Faculty: Department:	Clinical Sciences & International Health > Clinical Sciences Department
Digital Object Identifer (DOI):	https://doi.org/10.1093/trstmh/trv107
Depositing User:	Stacy Murtagh
Date Deposited:	30 Mar 2016 11:26
Last Modified:	06 Feb 2018 13:12
URI:	https://archive.lstmed.ac.uk/id/eprint/5822

Statistics

View details

Actions (login required)

Edit Item